Drug Discovery World
JULY 5, 2023
MG: I am responsible for Agilent’s cancer segment. A fulfilling part of my job is meeting the scientists, companies, and institutions at the forefront of ground-breaking research that are advancing patient health outcomes. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent?
Drug Discovery World
MAY 9, 2023
The recent passage of the FDA Modernization Act, which removed the requirement for animal testing when suitable alternatives are available, has highlighted the inadequacy of animal models most often used for in vivo research. Cancer is far more complex than the sum of its parts. Mice have long been heroes of preclinical cancer research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
FEBRUARY 11, 2021
Verily collaborates with Janssen to launch COVID-19 immune response study. Verily is partnering with Johnson & Johnson’s Janssen division to witness the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their homes. .
Drug Discovery World
OCTOBER 21, 2022
New research has identified immune targets for chemotherapy-resistant breast cancers. The research sheds light on the function of immune cells in these patients and will help future studies to enhance the anti-cancer immune response in breast cancer. 3D bioprinted breast cancer tumours.
Drug Discovery World
JULY 22, 2022
By Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences. As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours. However, adverse effects such as cytokine release syndrome (CRS) and neurotoxicity still occur.
Pharmaceutical Technology
JUNE 21, 2023
It is designed to enhance the function of regulatory T cells (Tregs) in vivo to treat the systemic and neuro-inflammation underlying autoimmune and neurodegenerative diseases. This suggests that the interventional strategy may lead to sustained suppressive immune responses and neuroprotection in PD.
Drug Discovery World
NOVEMBER 8, 2023
Sebastian Jaeger, PhD, Senior Scientist, ADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, on: ‘Evaluation of Fcab-drug conjugates as a novel antibody-based format for targeted drug delivery’.
Expert insights. Personalized for you.
98 
Let's personalize your content